Emerging EML4-ALK Variant 5 as a Concurrent Resistance Mechanism to Osimertinib in a Patient With EGFR E19del/T790M NSCLC

The management of patients with epidermal growth factor receptor (EGFR)-mutant, metastatic non–small-cell lung cancer (NSCLC) who become resistant to EGFR inhibitors remains challenging given the presence of complex and heterogeneous resistance mechanisms. READ ARTICLE

Clinical Lung Cancer DOI:10.1016/j.cllc.2020.05.009

Authors: Yan Yan, Guozhong Jiang, Weijie Ma, Tianhong Li, Liping Wang

Case StudyKirk SmithNovember 1, 2020Acquired resistance, EGFR mutation, EML4-ALK Variant 5, Histologic transformation, Metastatic NSCLC